Randomized trials found that injected semaglutide lowered C-reactive protein (CRP) in adults with overweight or obesity and without diabetes. The review’s comparison of weight and CRP changes uses percentage changes from two different starting values. It estimated a 40.90 percentage-point greater reduction in CRP versus placebo (95% CI 35.42–46.37 points greater). The review included nine trials with 6,239 participants in total.[2]
What the heart failure trials measured
The VA study of GLP-1 health outcomes examined a much broader set of outcomes in medical records. These randomized trials examined a narrower group and measured changes in an inflammation marker.
A separate analysis pooled two randomized STEP-HFpEF trials with 1,145 participants in the analysis set. Participants had obesity-related heart failure with preserved ejection fraction. Semaglutide lowered CRP more than placebo over 52 weeks. The analysis found no statistically clear differences in the treatment’s effects on symptoms, physical limitations, or six-minute walk distance across baseline CRP groups.[1]
What researchers found in inflammatory bowel disease
A matched study of people with inflammatory bowel disease treated with tirzepatide compared 3,042 people per group. The tirzepatide group had lower adjusted hazard of receiving intravenous steroids than the comparison group prescribed GLP-1 agonists (adjusted hazard ratio 0.81, 95% CI 0.68–0.94).[3]
Hospitalization, emergency visits, and intestinal surgery showed no statistically clear differences. The record-based study cannot establish that tirzepatide treats inflammatory bowel disease.[3]